Research Analysts’ price target changes for Wednesday, September 30th:
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price trimmed by JPMorgan Chase & Co. from $375.00 to $369.00. The firm currently has an overweight rating on the stock.
AnaptysBio (NASDAQ:ANAB) had its price target cut by JPMorgan Chase & Co. from $70.00 to $60.00. The firm currently has an overweight rating on the stock.
American Express (NYSE:AXP) had its target price trimmed by Citigroup Inc. from $355.00 to $340.00. Citigroup Inc. currently has a neutral rating on the stock.
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target boosted by JPMorgan Chase & Co. from $12.00 to $13.00. They currently have a neutral rating on the stock.
Banyan Gold (CVE:BYN) was given a C$3.00 price target by analysts at National Bank Financial. The firm currently has an outperform rating on the stock.
Cascades (TSE:CAS) had its target price increased by Canadian Imperial Bank of Commerce from C$17.50 to C$23.00.
Celanese (NYSE:CE) had its price target lowered by Citigroup Inc. from $60.00 to $58.00. The firm currently has a buy rating on the stock.
Cintas (NASDAQ:CTAS) had its price target raised by Citigroup Inc. from $180.00 to $181.00. They currently have a sell rating on the stock.
Eastman Chemical (NYSE:EMN) had its target price reduced by Citigroup Inc. from $81.00 to $76.00. They currently have a buy rating on the stock.
E3 Lithium (CVE:ETL) had its price target cut by ATB Cormark Capital Markets from C$4.00 to C$3.75.
Gibson Energy (TSE:GEI) had its price target raised by ATB Cormark Capital Markets from C$34.00 to C$35.00.
Hudbay Minerals (TSE:HBM) (NYSE:HBM) had its target price increased by Raymond James Financial, Inc. from C$42.00 to C$43.00.
Hudbay Minerals (TSE:HBM) (NYSE:HBM) had its target price increased by Haywood Securities from C$43.00 to C$45.00.
Liberty Energy (NYSE:LBRT) had its price target reduced by Citigroup Inc. from $28.50 to $27.50. The firm currently has a buy rating on the stock.
Levi Strauss & Co. (NYSE:LEVI) had its target price trimmed by Citigroup Inc. from $25.00 to $22.00. Citigroup Inc. currently has a neutral rating on the stock.
Lamb Weston (NYSE:LW) had its price target reduced by JPMorgan Chase & Co. from $52.00 to $46.00. They currently have a neutral rating on the stock.
Mullen Group (TSE:MTL) had its target price boosted by Royal Bank Of Canada from C$30.00 to C$32.00.
NOV (NYSE:NOV) had its target price trimmed by Citigroup Inc. from $22.00 to $21.00. Citigroup Inc. currently has a neutral rating on the stock.
Olin (NYSE:OLN) had its price target reduced by Citigroup Inc. from $19.00 to $17.00. Citigroup Inc. currently has a neutral rating on the stock.
Quarterhill (TSE:QTRH) had its price target trimmed by Canadian Imperial Bank of Commerce from C$4.50 to C$4.00.
Rogers Communications (TSE:RCI.B) (NYSE:RCI) had its price target lowered by National Bank Financial from C$62.00 to C$59.00.
Russel Metals (TSE:RUS) had its price target raised by Royal Bank Of Canada from C$92.00 to C$107.00.
Stella-Jones (TSE:SJ) had its target price trimmed by Royal Bank Of Canada from C$79.00 to C$76.00.
Sarepta Therapeutics (NASDAQ:SRPT) had its target price lowered by JPMorgan Chase & Co. from $23.00 to $20.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.
TELUS (TSE:T) (NYSE:TU) had its price target trimmed by National Bank Financial from C$15.00 to C$13.00.
Tamarack Valley Energy (TSE:TVE) was given a C$17.00 target price by analysts at Scotiabank. The firm currently has a sector outperform rating on the stock.
Vale (NYSE:VALE) had its price target increased by JPMorgan Chase & Co. from $21.00 to $22.00. They currently have an overweight rating on the stock.
Westlake (NYSE:WLK) had its target price lowered by Citigroup Inc. from $85.00 to $67.00. The firm currently has a neutral rating on the stock.
Westshore Terminals Investment (TSE:WTE) had its target price increased by Royal Bank Of Canada from C$44.00 to C$47.00.
Receive News & Ratings for Alnylam Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
